A COMPREHENSIVE STUDY ON AI-POWERED DRUG DISCOVERY: RAPID DEVELOPMENT OF PHARMACEUTICAL RESEARCH

Article *in* Journal of Emerging Technologies and Innovative Research · February 2021

CITATIONS
0

READS
111

1 author:

Venkateswaranaidu Kolluri
University of Mary Hardin–Baylor
24 PUBLICATIONS **23** CITATIONS

SEE PROFILE

A COMPREHENSIVE STUDY ON AI-POWERED DRUG DISCOVERY: RAPID DEVELOPMENT OF PHARMACEUTICAL RESEARCH

VENKATESWARANAIDU KOLLURI

Sr. Software Engineer, Department of Information Technology

***ABSTRACT*—The aim of this paper is to provide an overview of AI-assisted drug discovery, which involves AI technologies enabling the quick development of pharmaceutical research. The demand for unique therapeutics and increasing disease complexity leads conventional drug discovery methods to lamentable difficulties, which include time, cost, and inefficiency [1]. To counter the problem, human assisted technologies show proof-of-concept methods based on machine learning algorithms, data analytics, and computational modeling to vet drug candidates faster, and optimize for treatment [1]. The study analyzes the problem at the juncture of AI and drug discoveries, conducts a comprehensive literature review to review the current situation, and emphasizes the significance and advantages of utilizing AI in drug designing for the nation. Moreover, the article illustrates the future perspectives and predictions of AI for pharmaceutical studies and for healthcare innovation in the U.S.With AI algorithms getting more and more complex, sensitive, and autonomous, the issues connected with data privacy, patient consent, and the algorithm bias are arising. Implementing ethical principles and regulatory frameworks are of crucial importance to ensure the responsible use of AI in pharmaceutical research, as well as to maintain protection of patient rights and safety throughout the drug discovery process.**

***Keywords*— AI, artificial intelligence, drug discovery, pharmaceutical research, machine learning, computational modeling, healthcare innovation**

I. INTRODUCTION

Pharmaceutical research and development are redefining their landscape by digitizing biomedical research with AI technologies. Conventional drug-finding strategies, consisting of high expenditure, sloping timelines and low effectiveness, are being substituted by AI-powered techniques that utilize machine-learning algorithms, data-analytics and computational modeling to accelerate the identification of novel drugs. This paper will provide a view of AI-based drug discovery which in addition to revolutionizing the pharmaceutical industry will dramatically hasten treatment development. Innovation, by its nature, is altering demand for new therapies to meet the trade-offs in decision-making regarding patients´ wellbeing as well as the complexity of the disease mechanisms to make possible the work of experts in developing alternatives.

AI is a fast-emerging field which enables the scientists to process large volumes of biomedical data and predicts drug interactions as well as detecting the drug candidates with more power and sheer accuracy than at any time in history. Leveraging the power of AI [2], pharmaceutical companies will be able to speed up the drug discovery process, lower the costs and take the new medicines to the market faster by doing this, patients and the society as a whole will benefit. At the core of AI pharmaceutical research is the potential to extract meaning from extensive biological artifacts and convert them into practical understanding. Machine learning models, trained on broad datasets combining genomics, proteomics and clinical data, have the potential to hide patterns, biomarkers and lead to therapeutic developments that not all traditional analytical methods can achieve. Such an experience-based approach does not only shorten the period of finding out promising therapeutic candidates but also allows the development of individualized treatment plans based on the profiles of the patients as a whole, thus transforming the field of medicine, namely personalized medicine [3].

While the use of AI in drug discovery presents numerous opportunities, its adoption also comes with challenges. Problems, like data variability, algorithm stability and model understandability should be supported; otherwise, we cannot trust AI outputs and their replicability. Furthermore, the ethical questions of data privacy, patient consent, and algorithm bias should be dealt with with caution in order to prevent unanticipated side effects and adhere to ethical standards in pharmaceutical research [4]. Despite these issues, there is no doubt that AI, through its transformation capability, is one of the biggest drivers of innovation, collaboration, and study among researchers in the field of drug discovery and human health.

In this essay, we will explore the research problem that lies at the point where AI and pharmaceutical research meet, summarize the current practices in this area by reviewing the literature, and make an argument for the advantages of machine learning in drug discovery in the United States. Furthermore, we will look into the prospects and implications that AI could hold for the U.S. pharmaceutical industry development and innovation in healthcare that highlights that investments, policies, and collaboration come in handy to tap the real potential of AI in shaping the future of medicine.

II. RESEARCH PROBLEM

The primary research problem addressed in this study ison exploring the importance of revolutionizing drug discovery by integrating artificial intelligence (AI) technology comprehensively Modern drug discovery methods are handicapped by different challenges like high costs, long development timelines, and low success rates, which make it an indescribably demanding and resource-consumption process of discovering and producing new drugs. The AI application in drug discovery is built on the fact that this can speed up the process of discovery of novel drug candidates and of treatment strategies optimisation and can also lead to better patient outcomes. Earth, the only place in the universe where we have extraterrestrial intelligence contact. Firstly, there is a necessity to understand how AI-based techniques will fill in the gaps and enhance the current drug discovery approaches. This process involves exploration of the abilities and inadequacies of artificial intelligence algorithms in deciphering complex biological data, predicting drug-target interactions, and sorting out potential drug candidates that deserve further investigation [5]. Furthermore, the technical issues of data accuracy, algorithm reliability, and model comprehensibility must be addressed to maintain the authenticity of the AI-driven results research. This will help in understanding ethical and regulatory matters which arise from augmentation of AI in drug discovery processes.

III. LITERATURE REVIEW

A. AI IN DRUG DISCOVERY

The emergence of AI in drug discovery is an underlying process full of revolutionary progresses which are enabled by innovative computational procedures and data-oriented techniques. At the beginning, AI-based solutions were restricted to the rule-based systems and semi-intuitive algorithms, which rendered only limited data but were unable to solve the complexity of biological systems. Nonetheless, advances in the area of machine learning and deep learning driven by the availability of the vast biological databases and computational resources, made AI to be revolutionary in the process of drug discovery [6]. Machine learning (ML) algorithms have been widely used for analyzing various types of biological data which are represented by genomics, proteomics and chemical compounds. For example, support vector machines (SVMs), random forests, and neural networks are often applied to accomplish this purpose [7]. These algorithms can discriminate highly sophisticated connections and correlations all around large databases; therefore, drug-target interactions prediction, leads optimization and the successful medical treatment can be achieved by using these algorithms. Besides this, the birth of the deep learning architectures including convolutional neural networks (CNNs) and recurrent neural networks (RNNs) have changed the way data analysis is done by offering machine-learning algorithms that can be used to extract features from the raw data and provide more accurate predictions and insights [7].

The past several years have observed a coming together of computational as well as experimental approaches where AI algorithms determine the experimental design, target validation, and lead optimization. Artificial intelligence in the drug discovery process has led to accelerated identification of novel drug candidates, reduction in the cost of discovery and enhanced the success rate of clinical trials. Another important capability of AI is its ability to analyze collective biological interactions and predict drug response in the populations where treatment entirely depends on individual genetic profiles and disease characteristics.

[5].



Fig. 1 A bar graph showing the distribution of various AI techniques in Drug Discovery

B. AI-POWERED DRUG TARGET IDENTIFICATION

AI-based drug target identification is leading-edge technology for boosting drug discovery for different diseases. The use of these machine learning and data analytics tools allows for the analysis in detail of massive volumes of biological information with the objective of identifying molecules, proteins, or pathways that could be affected by drugs in order to treat different diseases [8]. One of the main advantages of AI in drug target identification is that it can sift through large-scale -omics or genomic, transcriptomic, proteomic, or metabolomic data - to discover useful relationships and patterns. Machine learning algorithms can be employed to analyze complex datasets in order to enhance the search of genes, proteins or signaling pathways that are dysregulated in disease states offering a clue for potential therapeutic targets [9]. Further, artificial intelligence algorithms can ease the process of personnel drug targeting by considering various multifaceted factors, such as their biological significance, the issue of druggability, and the resulting unwanted effects. Through the integration of varied data sources and by applying advanced feature selection skills, AI-based drug target identification platforms firstly seek out the most prominent candidates (according to the calculated for success$) with a consequent smoothing of the process of drug discovery. Moreover, AI algorithms are not only capable of handling conventional biological data but also features such as electronic health records, patient demographics, and clinical trial data, to identify new pathways and predictive biomarkers for personalized medicine strategies. It provides for a unified and holistic approach to therapy that assists in covering missed targets that can be obtained by traditional methods and deliver personalized treatments to the patients considering their distinct genetic makeup and other factors affecting their disease.



Fig. 2 AI in Drug Target Identification

C. AI-DRIVEN DRUG DESIGN AND OPTIMIZATION

Artificial intelligence (AI)-facilitated drug design and optimization of new therapeutics is a game changer in the drug development platform because of the higher efficacy and safety that they provide. This process takes advantage of the machine learning, in-silico modeling and structure-based screening approaches to speed up the process of finding and optimizing drug candidates with an aim to decrease the size of the drug development pipeline [10,11]. The capability of AI to process large amounts of chemical compounds and predict their properties such as activity, pharmacokinetics, and toxicity is one of importance. Machine learning algorithms are capable of conforming to the existing drug data for finding patterns and links among chemical structures and biological activities [12], which in turn makes possible the emergence of new compound structures with desired properties.

AI-driven drug design utilizes model extensions such as molecular docking/ molecular dynamics simulations to predict the interactions between a drug and its target protein. Such simulations are useful for researchers to test the binding strength and the selectivity of the molecules that can be adapted as drug candidates which then guide the researchers to select a lead compound for candidates for further optimization [13]. Moreover, drug candidates can be optimized by AI algorithms which can iteratively generate and screen chemical modifications to improve their potency, selectivity, and pharmacokinetic properties. The most time-consuming and labor-demanding step in the lead optimization process is executed with conventional methods; however, it can be significantly improved using AI-driven ones.

D. AI-Assisted Drug Repurposing and Combination Therapy

AI-driven repurposing and synergistic drug combination techniques represent innovative methods for drug development that aim to take advantage of existing drugs and to address unmet medical needs more effectively [14]. Drug repurposing, also referred to as drug repositioning, is the process of discovering new therapeutic uses for pre-existing drugs with indications other than those they were originally designed for. AI algorithms have proved that they significantly contribute to the drug discovery process through analyzing large-scale biomedical data, such as electronic health records and drug databases from where relationships between drugs, diseases, and biological pathways can be extracted [15,16]. Implementing machine learning methodologies, such as those based on networks and similarity, can enable AI to quickly determine potential candidates for repurposing based on their current known pharmacological profiles and suitability for the treatment of different diseases. On the other hand, AI-powered drug repurposing tools can rank drug candidates in accordance with different factors like their safety profiles, the way they act and their probability to be successful in clinical trials. The repurposing of existing drugs not only bypasses most of the time-consuming and expensive steps in the traditional drug development process, it also speeds up the time to market a new medication.



Fig. 1 A heatmap on AI-Assisted Drug Repurposing and Combination Therapy

IV. SIGNIFICANCE AND BENEFITS TO THE U.S

The AI-driven drug invention and development are highly valuable to the United States and have wide ranging significant benefits. First of all AI in pharmaceutical research can bring a complete rethinking of the drug discovery process that is going to help develop new designer medicines addressing a broad range of diseases [17]. AI technologies provide efficiency with streamlining of the drug development system, thus, cutting the time and cost that go to the market bringing new drugs, which at the end give patients a wider reach to treatment options. Additionally, artificial intelligence (AI)-driven drug discovery implies a potential of improving the positions of the U.S. pharmaceutical companies in a global market. Through supporting innovation and nurturing of partnerships among academic institutions, industry, and regulatory bodies, the US will stay on a path of successful biomedical research and development. This thereby boosts economic growth, creates high-paying jobs, and draws the life sciences industry players into the investments [18]. Moreover, AI in drug discovery not only poses solutions to the most crucial challenges in the United States healthcare such as drug-resistant pathogens, opioid epidemic, but also tobacco-related diseases [19,20]. The U.S. will be able to enhance patient outcomes, decrease healthcare expenditures, and offset the burden on the healthcare system by using AI to discover new therapeutic targets, repurpose existing drugs, and optimize treatment regimens.

V. FUTURE IN THE U.S

AI-driven drug development and discovery in the future of US healthcare will create a tremendous opportunity for medical research advancement, health outcomes improvement, and economic growth. As AI technologies gradually evolve and progress, their impact on pharmaceutical innovation in the U.S. is also expected to grow in importance. One of the major aspects of AI-powered drug discovery's future relates to the progressive assimilation of AI into pharmaceutical firms' R&D pipelines. AI is becoming more attractive to pharmaceutical companies to reduce the burden of drug discovery, to accelerate drug discovery, and to improve clinical trial design [21]. This trend is expected to extend with AI becoming an irreplaceable instrument for improving productivity, decreasing costs, and increasing the rate of drug development programs' success. Additionally, AI in the future will not work in just one sector of the life sciences but it will be used in the different sectors with more collaboration and convergence. AI technologies find their application in academic institutions, biotech startups, pharmaceutical companies, and government agencies as they are becoming partners to share data and resources. Such joint efforts are likely to push for innovation, emphasize interdisciplinary research, and speed up the transition from scientific discoveries to clinical application.

VI. CONCLUSION

This paper has offered a detailed analysis on how AI is transforming the pharmaceutical landscape and offering better solutions to patients' healthcare issues. By focusing on the study of this issue, a literature review, and a discussion of the relevance of this topic to the US, we see that AI technology has many advantages as a means of speeding up drug development, minimizing costs, and achieving personalized medicine. The most important role of AI-based drug discovery in the USA can be viewed as the contributor to the innovation, the process of economic growth, and the way to deal with impressive health issues. AI technologies can serve as a game changer in terms of maintaining the U.S.'s front line position with respect to biomedical research and development thus allowing attainment of such great ideas like precision medicine, drug repurposing and combination therapy. In summary on the topic, the future of AI- supported drug development in the United States is promising with new AI algorithms together with both data and computational resources being the future of the industry. Using these technologies and making collaboration between academia, industry and government possible, the U.S. can continue to make great strides and improve the lives of a lot of patients across the globe.

References

[1] N. Brown. Artificial Intelligence in Drug Discovery. Royal Society of Chemistry, 2020.
[2] J. Cassidy and B. Taylor, Artificial Intelligence in Oncology Drug Discovery and Development. BoD – Books on Demand, 2020.
[3] M. Chang, Artificial Intelligence for Drug Development, Precision Medicine, and Healthcare. CRC Press, 2020.
[4] M. Chang, AI for Drug Development and Well-being. 2020.
[5] F. Lake, "Artificial intelligence in drug discovery: what is new, and what is next?," Future Drug Discovery, vol. 1, no. 2, p. FDD19, Oct. 2019, doi: https://doi.org/10.4155/fdd-2019-0025
[6] A. Varun, "Artificial Intelligence (AI) in Drug Discovery and Medicine," Journal of Clinical Cases & Reports, vol. 2, no. 3, pp. 76–80, Jul. 2019, doi: https://doi.org/10.46619/joccr.2019.2-1043

[7] R. Lawrence, "Now the future, we see our dreams: artificial intelligence in drug discovery," Future Drug Discovery, vol. 1, no. 2, p. FDD22, Oct. 2019, doi: https://doi.org/10.4155/fdd-2019-0027

[8] K.-K. Mak and M. R. Pichika, "Artificial intelligence in drug development: present status and future prospects," Drug Discovery Today, vol. 24, no. 3, pp. 773–780, Mar. 2019, doi: https://doi.org/10.1016/j.drudis.2018.11.014. Available: https://www.sciencedirect.com/science/article/abs/pii/S1359644618300916

[9] P. Agrawal, "Artificial Intelligence in Drug Discovery and Development," Journal of Pharmacovigilance, vol. 06, no. 02, 2018, doi: https://doi.org/10.4172/2329-6887.1000e173

[10] A. Laghaee, C. Malcolm, J. Hallam, and P. Ghazal, "Artificial intelligence and robotics in high throughput post-genomics," Drug Discovery Today, vol. 10, no. 18, pp. 1253–1259, Sep. 2005, doi: https://doi.org/10.1016/s1359-6446(05)03581-6

[11] A. Bohr and K. Memarzadeh, Artificial Intelligence in Healthcare. Academic Press, 2020.

[12] R. Jagannathan, "AI and drug discovery : Search for new psychoactive candidates from cannabis sativa," Sep. 2020, doi: https://doi.org/10.1021/scimeetings.0c00478

[13] J. T. Chang and R. B. Altman, "Promises of text processing: natural language processing meets AI," Drug Discovery Today, vol. 7, no. 19, pp. 992–993, Oct. 2002, doi: https://doi.org/10.1016/s1359-6446(02)02457-1

[14] J. Kirchmair, "Editorial for the Special Section 'Artificial Intelligence in Drug Discovery,'" Drug Discovery Today: Technologies, Dec. 2020, doi: https://doi.org/10.1016/j.ddtec.2020.12.001

[15] E. Smalley, "AI-powered drug discovery captures pharma interest." Nature Biotechnology, vol. 35, no. 7, pp. 604-605, 2017, doi: 10.1038/nbt0717-604.

[16] M. Hervey, "Harnessing AI in drug discovery without losing patent protection." Drug Discovery Today, vol. 25, no. 6, pp. 949-950, 2020, doi: 10.1016/j.drudis.2020.03.007.

[17] A. Varun, "Artificial Intelligence (AI) in Drug Discovery and Medicine." Journal of Clinical Cases & Reports, vol. 2, no. 3, pp. 76-80, 2019, doi: 10.46619/joccr.2019.2-1043.

[18] K. Linton-Reid, "Introduction: An Overview of AI in Oncology Drug Discovery and Development." Artificial Intelligence in Oncology Drug Discovery and Development, 2020, doi: 10.5772/intechopen.92799.

[19] R. Dousa, "Toward the Clinic: Understanding Patient Perspectives on AI and Data-Sharing for AI-Driven Oncology Drug Development." Artificial Intelligence in Oncology Drug Discovery and Development, 2020, doi: 10.5772/intechopen.92787.

[20] M. Hervey, "Harnessing AI in drug discovery without losing patent protection." Drug Discovery Today, vol. 25, no. 6, pp. 949-950, 2020, doi: 10.1016/j.drudis.2020.03.007.

[21] N. Ai, M. D. Krasowski, W. J. Welsh, and S. Ekins, "Understanding nuclear receptors using computational methods." Drug Discovery Today, vol. 14, no. 9, pp. 486-494, 2009, doi: 10.1016/j.drudis.2009.03.003.